ALSO NOTED: GSK preps for India drug launches; Watson proceeds with challenge to Bayer drug;

> GlaxoSmithKline is preparing to launch its breast cancer drug Tykerb in India by early next year, with critical care and cardio drugs to follow. Report

> The 30-month clock is now ticking on Watson Pharmaceuticals' FDA application for its version of Bayer's Yaz contraceptive; the generics maker filed for approval two days after Bayer sued to stop the copycat drug. Release

> Japanese drug makers Daiichi Sankyo and Astellas Pharma, who are vying for the No. 2 ranking in their country, posted solid sales for the first half of the year. Report

> China blacklisted 16 misleading drug ads, bringing the total number of unacceptable ads aired since March to 26,644; some 11 drug makers have had their advertising licenses revoked for false advertising. Report

> A top Army trauma surgeon has drawn fire for using a NovoNordisk hemophilia drug off-label to stanch bleeding from war wounds, but he has plenty of fans who believe he's revolutionizing soldiers' care. Report

> Pfizer researchers rolled out the data on torcetrapib--the would-be blockbuster felled by data indicating a heightened risk of death and stroke--at the annual scientific meeting of the American Heart Association. And the numbers were being carefully scrutinized by Merck and Roche, which are advancing a group of similar drugs. Report

> Momenta Pharmaceuticals took its turn at the Wall Street whipping post as investors respond to the news that the FDA has rejected its generic version of the anti-clotting drug Lovenox, which is made by Sanofi. Report

> Novartis is staring at some serious problems rolling out its diabetes drug Galvus. Report

> Neural stem cells were used to stimulate the learning and memory abilities of mice engineered to mimic the severe disabilities produced by Alzheimer's and stroke. Report

> A chemistry professor at the University of Illinois at Urbana-Champagne says that an iron-based catalyst she developed with a colleague could speed the drug development and manufacturing. Report

And Finally... A genetic modification of a single metabolism gene helped scientists create a new breed of supermouse that can run faster and longer than ever possible. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.